**9. Conclusions**

Fabrication techniques for conductive and biodegradable scaffolds could affect the physical and mechanical properties of the scaffold. Injectable scaffolds have the potential to be the most suitable low-risk method for TE-related medical treatments. Optimising the scaffold's properties to resemble the properties of human ECM tissue is an ideal goal to realise a scaffold's potential. This will lower the property gap between the scaffold and the tissues at the implantation site. Identical biodegradation and tissue regeneration rates are pivotal to ensure optimised healing. The by-products of scaffolds' degradation should be non-toxic and biocompatible to inhibit immunogenic effects, particularly at the implantable site. In addition to the scaffold's degradation rate, a proof of concept regarding biodegradation should be studied in vivo and in vitro. The biodegradability of CP-based scaffolds should be prioritised, without neglecting their electrical conductivity behaviour in future studies. The uses of CPs in biomedical applications are very broad, and each different CP has its own potential and speciality. Research, at the basic level, must be carried out, together with a focus on the varied aspects of study environment (in vitro and in vivo studies). This is because human bodies are very complex. Extensive studies focusing on the biocompatibility and immunogenicity of an electrically conductive scaffold composite must be conducted to obtain a clearer view of the use of CPs for tissue engineering applications.

**Funding:** This work was carried by the NPRP grant # NPRP11S-1221-170116 from the Qatar National Research Fund (a member of Qatar Foundation). The statements made herein are solely the responsibility of the authors.

**Data Availability Statement:** Not applicable.

**Acknowledgments:** The authors wish to thank Norzawani Buang M Yassin, of Imperial College London, United Kingdom, for the useful discussion.

**Conflicts of Interest:** The authors declare no conflict of interest.
